Approved for Intermediate-Risk Patients TAVR With the Edwards SAPIEN 3 Valve This is TAVR Today—
Better Than Surgery for Intermediate-Risk Patients*
75% 1.1%
All-cause Mortality† 1.0% Lower Than Surgery† Disabling Stroke†
The PARTNER Trials represent the largest, most robust comparative body of evidence in the history of aortic valve replacement.
› Learn more at
NewHeartValve.com/hcp
* The PARTNER II Trial intermediate-risk cohort, VI population (n=2,005); the diff erence in the primary endpoint (composite of all-cause mortality, all stroke, and ≥ moderate aortic regurgitation at one year) event rate between TAVR with the SAPIEN 3 valve and surgery appeared to be clinically signifi cant.
†
The PARTNER II Trial intermediate-risk cohort 30-day unadjusted clinical event rates for TAVR with the SAPIEN 3 valve, AT population (n=1,077).
See adjacent page for Important Safety Information. CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.
Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3,
NewHeartValve.com, PARTNER, PARTNER II, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation. © 2017 Edwards Lifesciences Corporation. All rights reserved. PP--US-0730 v5.0 Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA •
edwards.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
